Avadel Pharmaceuticals plc (AVDL) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

Avadel Pharmaceuticals plc (AVDL)

View Full Profile →

Intrinsic Value

DCF Not Suitable for AVDL

Revenue ($249M) below $1B threshold — insufficient business scale for DCF.

Alternative Approach:

Use EV/Sales vs. industry peers for growth-stage companies.

Frequently Asked Questions

Is AVDL stock undervalued or overvalued?

Insufficient data to compute DCF valuation for AVDL. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is AVDL's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is AVDL's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For AVDL, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.